Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

MLA

Amir I. Tukhvatulin, et al. “Safety and Immunogenicity of RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine against SARS-CoV-2 in Healthy Adolescents: An Open-Label, Non-Randomized, Multicenter, Phase 1/2, Dose-Escalation Study.” Frontiers in Immunology, vol. 14, Aug. 2023. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1228461.

APA

Amir I. Tukhvatulin, Inna V. Dolzhikova, Alina S. Dzharullaeva, Daria M. Grousova, Anna V. Kovyrshina, Olga V. Zubkova, Ilya D. Zorkov, Anna A. Iliukhina, Artem Y. Shelkov, Alina S. Erokhova, Olga Popova, Tatiana A. Ozharovskaia, Denis I. Zrelkin, Fatima M. Izhaeva, Dmitry V. Shcheblyakov, Ilias B. Esmagambetov, Elisaveta A. Tokarskaya, Natalia A. Nikitenko, Nadezhda L. Lubenets, … Alexander L. Gintsburg. (2023). Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1228461

Chicago

Amir I. Tukhvatulin, Inna V. Dolzhikova, Alina S. Dzharullaeva, Daria M. Grousova, Anna V. Kovyrshina, Olga V. Zubkova, Ilya D. Zorkov, et al. 2023. “Safety and Immunogenicity of RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine against SARS-CoV-2 in Healthy Adolescents: An Open-Label, Non-Randomized, Multicenter, Phase 1/2, Dose-Escalation Study.” Frontiers in Immunology 14 (August). doi:10.3389/fimmu.2023.1228461.